Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Reactive oxygen species levels control NF-κB activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes.

Meunier M, Ancelet S, Lefebvre C, Arnaud J, Garrel C, Pezet M, Wang Y, Faure P, Szymanski G, Duployez N, Preudhomme C, Biard D, Polack B, Cahn JY, Moulis JM, Park S.

Oncotarget. 2017 Nov 6;8(62):105510-105524. doi: 10.18632/oncotarget.22299. eCollection 2017 Dec 1.

2.

Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.

Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann WK, Schrezenmeier H.

Ann Hematol. 2013 Jan;92(2):191-8. doi: 10.1007/s00277-012-1594-z. Epub 2012 Oct 17.

PMID:
23073603
3.

Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.

Maurillo L, Breccia M, Buccisano F, Voso MT, Niscola P, Trapè G, Tatarelli C, D'Addosio A, Latagliata R, Fenu S, Piccioni AL, Fragasso A, Aloe Spiriti MA, Refrigeri M, Criscuolo M, Musto P, Venditti A.

Eur J Haematol. 2015 Jul;95(1):52-6. doi: 10.1111/ejh.12476. Epub 2015 Mar 12.

PMID:
25764148
4.

Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity.

Jiménez-Solas T, López-Cadenas F, Aires-Mejía I, Caballero-Berrocal JC, Ortega R, Redondo AM, Sánchez-Guijo F, Muntión S, García-Martín L, Albarrán B, Alonso JM, Del Cañizo C, Hernández-Hernández Á, Díez-Campelo M.

Br J Haematol. 2019 Jun 6. doi: 10.1111/bjh.16013. [Epub ahead of print]

PMID:
31172513
5.

Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging.

Messa E, Carturan S, Maffè C, Pautasso M, Bracco E, Roetto A, Messa F, Arruga F, Defilippi I, Rosso V, Zanone C, Rotolo A, Greco E, Pellegrino RM, Alberti D, Saglio G, Cilloni D.

Haematologica. 2010 Aug;95(8):1308-16. doi: 10.3324/haematol.2009.016824. Epub 2010 Jun 9.

6.

Deferasirox exposure induces reactive oxygen species and reduces growth and viability of myelodysplastic hematopoietic progenitors.

Pullarkat V, Sehgal A, Li L, Meng Z, Lin A, Forman S, Bhatia R.

Leuk Res. 2012 Aug;36(8):966-73. doi: 10.1016/j.leukres.2012.03.018. Epub 2012 Apr 12.

PMID:
22502920
7.

The oral iron chelator deferasirox inhibits NF-κB mediated gene expression without impacting on proximal activation: implications for myelodysplasia and aplastic anaemia.

Banerjee A, Mifsud NA, Bird R, Forsyth C, Szer J, Tam C, Kellner S, Grigg A, Motum P, Bentley M, Opat S, Grigoriadis G.

Br J Haematol. 2015 Feb;168(4):576-82. doi: 10.1111/bjh.13151. Epub 2014 Oct 1.

PMID:
25271366
8.

Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload.

Kim IH, Moon JH, Lim SN, Sohn SK, Kim HG, Lee GW, Kim YS, Lee HS, Kwon KY, Kim SH, Park KT, Chung JS, Lee WS, Lee SM, Hyun MS, Kim H, Ryoo HM, Bae SH, Joo YD.

Transfusion. 2015 Jul;55(7):1613-20. doi: 10.1111/trf.13036. Epub 2015 Mar 11.

PMID:
25764017
9.

Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes.

Zeidan AM, Hendrick F, Friedmann E, Baer MR, Gore SD, Sasane M, Paley C, Davidoff AJ.

J Comp Eff Res. 2015 Aug;4(4):327-40. doi: 10.2217/cer.15.20.

10.

Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia.

Cheong JW, Kim HJ, Lee KH, Yoon SS, Lee JH, Park HS, Kim HY, Shim H, Seong CM, Kim CS, Chung J, Hyun MS, Jo DY, Jung CW, Sohn SK, Yoon HJ, Kim BS, Joo YD, Park CY, Min YH; Korean Society of Hematology Acute Myeloid Leukemia/Myelodysplastic Syndrome Working Party.

Transfusion. 2014 Jun;54(6):1542-51. doi: 10.1111/trf.12507. Epub 2013 Dec 3.

PMID:
24313463
11.

Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox.

Kikuchi S, Kobune M, Iyama S, Sato T, Murase K, Kawano Y, Takada K, Ono K, Kaneko Y, Miyanishi K, Sato Y, Hayashi T, Takimoto R, Kato J.

Free Radic Biol Med. 2012 Aug 15;53(4):643-8. doi: 10.1016/j.freeradbiomed.2012.06.006. Epub 2012 Jun 15.

PMID:
22705364
12.

Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).

Angelucci E, Santini V, Di Tucci AA, Quaresmini G, Finelli C, Volpe A, Quarta G, Rivellini F, Sanpaolo G, Cilloni D, Salvi F, Caocci G, Molteni A, Vallisa D, Voso MT, Fenu S, Borin L, Latte G, Alimena G, Storti S, Piciocchi A, Fazi P, Vignetti M, Tura S.

Eur J Haematol. 2014 Jun;92(6):527-36. doi: 10.1111/ejh.12300. Epub 2014 Apr 10.

PMID:
24580147
13.

Synergistic inhibitory effects of deferasirox in combination with decitabine on leukemia cell lines SKM-1, THP-1, and K-562.

Li N, Chen Q, Gu J, Li S, Zhao G, Wang W, Wang Z, Wang X.

Oncotarget. 2017 May 30;8(22):36517-36530. doi: 10.18632/oncotarget.16583.

14.

Hematopoietic recovery after administration of deferasirox for transfusional iron overload in a case of myelodysplastic syndrome.

OKABE H, SUZUKI T, OMORI T, MORI M, UEHARA E, HATANO K, UEDA M, MATSUYAMA T, TOSHIMA M, QZAKI K, NAGAI T, MUROI K, OZAWA K.

Rinsho Ketsueki. 2009 Nov;50(11):1626-9. Review.

PMID:
20009438
15.

Iron Overload in Myelodysplastic Syndromes: Pathophysiology, Consequences, Diagnosis, and Treatment.

Lyle L, Hirose A.

J Adv Pract Oncol. 2018 May-Jun;9(4):392-405. Epub 2018 May 1. Review.

16.

Effect of deferasirox + erythropoietin vs erythropoietin on erythroid response in Low/Int-1-risk MDS patients: Results of the phase II KALLISTO trial.

Gattermann N, Coll R, Jacobasch L, Allameddine A, Azmon A, DeBonnett L, Bruederle A, Jin J; KALLISTO study investigators.

Eur J Haematol. 2018 May 19. doi: 10.1111/ejh.13096. [Epub ahead of print]

PMID:
29777631
17.

Reactive oxygen species mediated T lymphocyte abnormalities in an iron-overloaded mouse model and iron-overloaded patients with myelodysplastic syndromes.

Chen J, Lu WY, Zhao MF, Cao XL, Jiang YY, Jin X, Xu P, Yuan TT, Zhang YC, Chai X, Meng JX, Li Q, Xiao X, Mu J, Li DG, Qi AP.

Ann Hematol. 2017 Jul;96(7):1085-1095. doi: 10.1007/s00277-017-2985-y. Epub 2017 Apr 18.

PMID:
28421266
18.

Iron overload promotes erythroid apoptosis through regulating HIF-1a/ROS signaling pathway in patients with myelodysplastic syndrome.

Zheng QQ, Zhao YS, Guo J, Zhao SD, Song LX, Fei CM, Zhang Z, Li X, Chang CK.

Leuk Res. 2017 Jul;58:55-62. doi: 10.1016/j.leukres.2017.04.005. Epub 2017 Apr 23.

PMID:
28460338
19.
20.

Transfusion-dependent low-risk myelodysplastic patients receiving deferasirox: Long-term follow-up.

Improta S, Villa MR, Volpe A, Lombardi A, Stiuso P, Cantore N, Mastrullo L.

Oncol Lett. 2013 Dec;6(6):1774-1778. Epub 2013 Oct 10.

Supplemental Content

Support Center